• 1
    Harmar AJ. Family-B G-protein-coupled receptors. Genome Biol. 2001;2:3013.13013.10.
  • 2
    Mannstadt M, Juppner H, Gardella TJ. Receptors for PTH and PTHrP: their biological importance and functional properties. Am J Physiol. 1999;277:F665F675.
  • 3
    Schipani E, Karga H, Karaplis AC, et al. Identical complementary deoxyribonucleic acids encode a human renal and bone parathyroid hormone (PTH)/PTH-related peptide receptor. Endocrinology. 1993;132:21572165.
  • 4
    Kong X-F, Schipani E, Lanske B, et al. The rat, mouse and human genes encoding the receptor for parathyroid hormone and parathyroid hormone-related peptide are highly homologous. Biochem Biophys Res Commun. 1994;200:12901299.
  • 5
    Shyu JF, Inoue D, Baron R, Horne WC. The deletion of 14 amino acids in the seventh transmembrane domain of a naturally occurring calcitonin receptor isoform alters ligand binding and selectively abolishes coupling to phospholipase C. J Biol Chem. 1996;271:3112731134.
  • 6
    Grammatopoulos DK, Dai Y, Randeva HS, et al. A novel spliced variant of the type 1 corticotropin-releasing hormone receptor with a deletion in the seventh transmembrane domain present in the human pregnant term myometrium and fetal membranes. Mol Endocrinol. 1999;13:21892202.
  • 7
    Grinninger C, Wang W, Oskoui KB, Voice JK, Goetzl EJ. A natural variant type II G protein-coupled receptor for vasoactive intestinal peptide with altered function. J Biol Chem. 2004;279:4025940262.
  • 8
    Markovic D, Lehnert H, Levine MA, Grammatopoulos DK. Structural determinants critical for localization and signaling within the seventh transmembrane domain of the type 1 corticotropin releasing hormone receptor: lessons from the receptor variant R1d. Mol Endocrinol. 2008;22:25052519.
  • 9
    Urena P, Kong XF, Abou-Samra AB, et al. Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology. 1993;133:617623.
  • 10
    Jobert AS, Fernandes I, Turner G, et al. Expression of alternatively spliced isoforms of the parathyroid hormone (PTH)/PTH-related peptide receptor messenger RNA in human kidney and bone cells. Mol Endocrinol. 1996;10:10661076.
  • 11
    Amizuka N, Lee HS, Kwan MY, et al. Cell-specific expression of the parathyroid hormone (PTH)/PTH-related peptide receptor gene in kidney from kidney-specific and ubiquitous promoters. Endocrinology. 1997;138:469481.
  • 12
    Ding C, Racusen LC, Wilson P, Burrow C, Levine MA. Identification of an alternatively spliced form of PTH/PTHrP receptor mRNA in immortalized renal tubular cells. J Bone Miner Res. 1995;10 (Suppl 1): S484.
  • 13
    Schipani E, Weinstein LS, Bergwitz C, et al. Pseudohypoparathyroidism type Ib is not caused by mutations in the coding exons of the human parathyroid hormone (PTH)/PTH-related peptide receptor gene. J Clin Endocrinol Metab. 1995;80:16111621.
  • 14
    Fukumoto S, Suzawa M, Takeuchi Y, et al. Absence of mutations in parathyroid hormone (PTH) PTH-related protein receptor complementary deoxyribonucleic acid in patients with pseudohypoparathyroidism type Ib. J Clin Endocrinol Metab. 1996;81:25542558.
  • 15
    Suarez F, Lebrun JJ, Lecossier D, Escoubet B, Coureau C, Silve C. Expression and modulation of the parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid in skin fibroblasts from patients with type Ib pseudohypoparathyroidism. J Clin Endocrinol Metab. 1995;80:965970.
  • 16
    Bettoun JD, Minagawa M, Kwan MY, et al. Cloning and characterization of the promoter regions of the human parathyroid hormone (PTH)/PTH-related peptide receptor gene: analysis of deoxyribonucleic acid from normal subjects and patients with pseudohypoparathyroidism type 1b. J Clin Endocrinol Metab. 1997;82:10311040.
  • 17
    Racusen LC, Wilson PD, Hartz PA, Fivush BA, Burrow CR. Renal proximal tubular epithelium from patients with nephropathic cystinosis: immortalized cell lines as in vitro model systems. Kidney Int. 1995;48:536543.
  • 18
    Racusen LC, Monteil C, Sgrignoli A, et al. Cell lines with extended in vitro growth potential from human renal proximal tubule: Characterization, response to inducers, and comparison with established cell lines. J Lab Clin Med. 1997;129:318329.
  • 19
    Wang B, Bisello A, Yang Y, Romero GG, Friedman PA. NHERF1 regulates parathyroid hormone receptor membrane retention without affecting recycling. J Biol Chem. 2007;282:3621436222.
  • 20
    Wang B, Yang Y, Friedman PA. Na/H Exchange regulator factor 1, a novel Akt-associating protein, regulates extracellular signal-related signaling through a B-Raf-mediated pathway. Mol Biol Cell. 2008;19:16371645.
  • 21
    Wang B, Yang Y. Generation of human PTH1R construct with Flag epitope located internally: comparison of two-fragment assembly by using PCR overlap extension or ligase. J Biomol Tech. 2009;20:195200.
  • 22
    Ferrandon S, Feinstein TN, Castro M, et al. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol. 2009;5:734742.
  • 23
    Sneddon WB, Syme CA, Bisello A, et al. Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EBP50). J Biol Chem. 2003;278:4378743796.
  • 24
    Bisello A, Greenberg Z, Behar V, Rosenblatt M, Suva LJ, Chorev M. Role of glycosylation in expression and function of the human parathyroid hormone parathyroid hormone-related protein receptor. Biochemistry. 1996;35:1589015895.
  • 25
    Nikolaev VO, Bunemann M, Hein L, Hannawacker A, Lohse MJ. Novel single chain cAMP sensors for receptor-induced signal propagation. J Biol Chem. 2004; 3721537218.
  • 26
    Vilardaga JP, Nikolaev VO, Lorenz K, Ferrandon S, Zhuang Z, Lohse MJ. Conformational cross-talk between α2A-adrenergic and mu-opioid receptors controls cell signaling. Nat Chem Biol. 2008;4:126131.
  • 27
    Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with ImageJ. Biophotonics Int. 2004;11:3642.
  • 28
    Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol. 2001;305:567580.
  • 29
    Bermak JC, Li M, Bullock C, Zhou QY. Regulation of transport of the dopamine D1 receptor by a new membrane-associated ER protein. Nat Cell Biol. 2001;3:492498.
  • 30
    Schulein R, Hermosilla R, Oksche A, et al. A dileucine sequence and an upstream glutamate residue in the intracellular carboxyl terminus of the vasopressin V2 receptor are essential for cell surface transport in COS.M6 cells. Molecular Pharmacol. 1998;54:525535.
  • 31
    Thielen A, Oueslati M, Hermosilla R, et al. The hydrophobic amino acid residues in the membrane-proximal C tail of the G protein-coupled vasopressin V2 receptor are necessary for transport-competent receptor folding. FEBS Lett. 2005;579:52275235.
  • 32
    Marchese A, Paing MM, Temple BR, Trejo J. G protein-coupled receptor sorting to endosomes and lysosomes. Annu Rev Pharmacol Toxicol. 2008;48:601629.
  • 33
    Ulloa-Aguirre A, Conn PM. Targeting of G protein-coupled receptors to the plasma membrane in health and disease. Front Biosci. 2009;14:973994.
  • 34
    Margeta-Mitrovic M, Jan YN, Jan LY. A trafficking checkpoint controls GABAB receptor heterodimerization. Neuron. 2000;27:97106.
  • 35
    Poyner DR, Sexton PM, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002;54:233246.
  • 36
    Rey A, Manen D, Rizzoli R, Caverzasio J, Ferrari SL. Proline-rich motifs in the PTH/PTHrP-receptor C-terminus mediate scaffolding of c-Src with ß-arrestin2 for ERK1/2 activation. J Biol Chem. 2006; 3818138188.
  • 37
    Pioszak AA, Harikumar KG, Parker NR, Miller LJ, Xu HE. Dimeric arrangement of the parathyroid hormone receptor and a structural mechanism for ligand-induced dissociation. J Biol Chem. 2010; [Epub ahead of print].
  • 38
    Seck T, Baron R, Horne WC. The alternatively spliced Δe13 transcript of the rabbit calcitonin receptor dimerizes with the C1a isoform and inhibits its surface expression. J Biol Chem. 2003;278:2308523093.
  • 39
    Mahon MJ, Bonacci TM, Divieti P, Smrcka AV. A docking site for G protein βγ subunits on the parathyroid hormone 1 receptor supports signaling through multiple pathways. Mol Endocrinol. 2006;20:136146.
  • 40
    Huang Z, Chen Y, Nissenson RA. The cytoplasmic tail of the G-protein-coupled receptor for parathyroid hormone and parathyroid hormone-related protein contains positive and negative signals for endocytosis. J Biol Chem. 1995;270:151156.
  • 41
    Weinman EJ, Hall RA, Friedman PA, Liu-Chen LY, Shenolikar S. The association of NHERF adaptor proteins with G protein-coupled receptors and receptor tyrosine kinases. Annu Rev Physiol. 2006;68:491505.
  • 42
    Wheeler D, Garrido JL, Bisello A, Kim YK, Friedman PA, Romero G. Regulation of PTH1R dynamics, traffic and signaling by the Na+/H+ exchanger regulatory factor-1 (NHERF1) in rat osteosarcoma ROS 17/28 cells. Mol Endocrinol. 2008;22:11631170.
  • 43
    Wang B, Yang Y, Abou-Samra AB, Friedman PA. NHERF1 regulates parathyroid hormone receptor desensitization; interference with ß-arrestin binding. Mol Pharmacol. 2009;75:11891197.
  • 44
    Bouley R, Lin HY, Raychowdhury MK, Marshansky V, Brown D, Ausiello DA. Downregulation of the vasopressin type 2 receptor after vasopressin-induced internalization: involvement of a lysosomal degradation pathway. Am J Physiol Cell Physiol. 2005;288:C1390C1401.
  • 45
    Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the long road to destruction. Nat Cell Biol. 2005;7:766772.
  • 46
    Schwieger I, Lautz K, Krause E, Rosenthal W, Wiesner B, Hermosilla R. Derlin-1 and p97/valosin-containing protein mediate the endoplasmic reticulum-associated degradation of human V2 vasopressin receptors. Mol Pharmacol. 2008;73:697708.
  • 47
    van Ommen GJ, van Deutekom J, Aartsma-Rus A. The therapeutic potential of antisense-mediated exon skipping. Curr Opin Mol Ther. 2008;10:140149.
  • 48
    Miriami E, Margalit H, Sperling R. Conserved sequence elements associated with exon skipping. Nucleic Acids Res. 2003;31:19741983.
  • 49
    Juppner H, Bastepe M. Different mutations within or upstream of the GNAS locus cause distinct forms of pseudohypoparathyroidism. J Pediatr Endocrinol Metab. 2006;19 (Suppl 2): 641646.
  • 50
    Bastepe M, Juppner H. GNAS locus and pseudohypoparathyroidism. Horm Res. 2005;63:6574.
  • 51
    Mantovani G, de Sanctis L, Barbieri AM, et al. Pseudohypoparathyroidism and GNAS epigenetic defects: clinical evaluation of Albright hereditary osteodystrophy and molecular analysis in 40 patients. J Clin Endocrinol Metab. 2010;95:651658.